Invitae Transthyretin Amyloidosis Test


Test description

This test analyzes the TTR gene associated with familial transthyretin amyloidosis—the most common type of familial amyloid polyneuropathy.

Individuals with clinical symptoms of transthyretin amyloidosis may benefit from diagnostic genetic testing to better understand risks, confirm a diagnosis, or inform management. Asymptomatic individuals within a family with a known pathogenic variant may also benefit, as it may clarify their own personal risk of developing transthyretin amyloidosis or inform medical management.

Order test

Primary panel (1 gene)


Alternative tests to consider

Transthyretin amyloidosis can also be ordered as part of broader panels to test for cardiomyopathy disorders. Depending on the individual’s clinical and family history, one of these broader panels may be appropriate. Any of these broader panels can be ordered at no additional charge.

Transthyretin amyloidosis

Transthyretin amyloidosis is characterized by amyloidosis, the buildup of abnormal amyloid protein deposits in the body. Transthyretin amyloidosis can present with progressive axonal sensory autonomic and motor neuropathy and infiltrative cardiomyopathy. Additional features may include conduction block, nephropathy, vitreous opacities, or neurological symptoms related to CNS amyloidosis. Transthyretin amyloidosis can also be an acquired condition, due to age-related deposition of TTR, referred to as senile systemic amyloidosis.

The TTR gene is the only gene associated with transthyretin amyloidosis. Sequence analysis identifies >99% of pathogenic variants.

Transthyretin amyloidosis is inherited in an autosomal dominant pattern.

Transthyretin amyloidosis exhibits reduced penetrance, meaning that not everyone who inherits a predisposition to transthyretin amyloidosis will develop the disease. Homozygosity for common TTR pathogenic variants can be associated with earlier age of onset—though not exclusively, as some homozygous individuals remain asymptomatic. The penetrance has been observed to differ by population, with a higher penetrance in Portuguese population, as compared to Swedish and French populations.

Some TTR variants predispose to cardiomyopathy, with or without neuropathy. Other TTR variants are primarily associated with features of neuropathy. Significant clinical variability exists, even within the same family. However, as amyloidosis progresses, affected individuals typically experience more symptoms as amyloid deposits accumulate in more tissues.

The prevalence of transthyretin amyloidosis is population-specific, with certain variants accounting for the majority of transthyretin amyloidosis in populations where it is endemic. The most common pathogenic TTR variant, Val40Met, has the highest frequency in Portuguese, Japanese, and Swedish populations. The Val122Ile variant occurs in approximately 4% of individuals of African American ancestry.

This test may be considered for individuals with:

  • unexplained neuropathic pain or progressive sensory disturbance
  • autonomic nerve dysfunction
  • unexplained cardiomyopathy, with or without arrhythmia
  • vitreous body inclusions
  • a family history of neuropathic disease, particularly when associated with heart failure

For links to published management guidelines for cardiology conditions, please refer to our Management guidelines page.

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence, and select noncoding variants. Our assay provides a Q30 quality-adjusted mean coverage depth of 350x (50x minimum, or supplemented with additional analysis). Variants classified as pathogenic or likely pathogenic are confirmed with orthogonal methods, except individual variants that have high quality scores and previously validated in at least ten unrelated samples.

Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
TTR NM_000371.3